At Texas Retina, we remain committed to conducting ongoing research that will continue to advance retinal care — a value instilled by the pioneering physicians who founded our practice more than 50 years ago.
That is why our physicians have participated in more than 100 national clinical trials over the past 20+ years, offering our patients access to promising new treatments for a variety of retina conditions, including age-related macular degeneration (AMD), ocular melanoma (cancer), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and uveitis.
We recently opened six new clinical trials:
Diabetic Macular Edema
EYP-1901-303 (COMO) (Dallas Main, Plano) — A Phase 3, multicenter, prospective, randomized, double-masked, parallel-group study of EYP-1901.
Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)
APL3007-GA-201 (Dallas Main) — A Phase 2, randomized, placebo-controlled, multicenter, masked study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syfovre/pegcetacoplan (APL-2) in patients with GA.
Wet Macular Degeneration
20250115 Amgen (Fort Worth) — A randomized, double-masked, comparative clinical study evaluating the efficacy, safety, and immunogeniticty of ABP938 8mg versus Eylea HD.
ADVM-022-13 (Dallas Main, Fort Worth) — A multi-centered, randomized, double-masked, active-comparator-controlled, Phase 3 study to evaluate the efficacy and safety of Ixoberogrene soroparvovec.
MK-8748-002 (Dallas Main, Plano, Arlington) — A randomized, double-masked, multicenter, 3-arm, pivotal phase 2/3 study to evaluate the efficacy and safety of IVT EYE201/MK-8748 compared to aflibercept 2mg in participants with NVAMD.
MK-8748-003 TORRONTES (Fort Worth) — A randomized, double-masked, multicenter, 3-arm, pivotal phase 2/3 study to evaluate the efficacy and safety of IVT EYE201/MK-8748 compared to aflibercept 2mg in participants with NVAMD.
We currently have a total of 15 open studies. Click here to view all of our actively enrolling clinical trials.
For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.